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Abstract
The purpose of our study was to understand if Toll-like receptor 9 (TLR9) activation could contribute to the control of
inflammation in Sjogren’s syndrome. To this end, we manipulated TLR9 signaling in non-obese diabetic (NOD) and TLR9
2/2
mice using agonistic CpG oligonucleotide aptamers, TLR9 inhibitors, and the in-house oligonucleotide BL-7040. We then
measured salivation, inflammatory response markers, and expression of proteins downstream to NF-kB activation pathways.
Finally, we labeled proteins of interest in salivary gland biopsies from Sjogren’s syndrome patients, compared to Sicca
syndrome controls. We show that in NOD mice BL-7040 activates TLR9 to induce an alternative NF-kB activation mode
resulting in increased salivation, elevated anti-inflammatory response in salivary glands, and reduced peripheral AChE
activity. These effects were more prominent and also suppressible by TLR9 inhibitors in NOD mice, but TLR9
2/2 mice were
resistant to the salivation-promoting effects of CpG oligonucleotides and BL-7040. Last, salivary glands from Sjogren’s
disease patients showed increased inflammatory and decreased anti-inflammatory biomarkers, in addition to decreased
levels of alternative NF-kB pathway proteins. In summary, we have demonstrated that activation of TLR9 by BL-7040 leads
to non-canonical activation of NF-kB, promoting salivary functioning and down-regulating inflammation. We propose that
BL-7040 could be beneficial in treating Sjogren’s syndrome and may be applicable to additional autoimmune syndromes.
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Introduction
Sjo ¨gren’s syndrome (SjS) is a common syndrome affecting
various exocrine cells. It emerges at all ages, peaking in the fourth
and fifth decade, and has a female to male ratio of 9:1 [1]. SjS is
characterized by extraglandular manifestations, severe salivary
gland hypo-function, infiltration of lymphocytes and plasmacytoid
dendritic cells (pDCs) and decreased salivary secretion [2]. Diverse
auto-antibodies indicating B cells activation and loss of immune
tolerance are characteristic of SjS [3]. Serum auto-antibodies
directed to the ribo-nuclear proteins SS-A/Ro and SS-B/La are
believed to affect disease pathogenesis via Toll-like receptor (TLR)
signaling [4].
TLRs expressed on the cell surface or endosomal membranes of
innate immune system cells detect pathogens and inherent
apoptotic processes releasing DNA fragments [5]. Activation of
these receptors can lead to interferon (IFN)-mediated stimulation
of adaptive immunity, pro-inflammatory reactions mediated by
the transcriptional regulator NFkB, and possibly an additional,
alternative anti-inflammatory activation of NFkB [6,7].
Of the different TLRs, TLR9 and TLR7 are considered most
relevant to autoimmunity [5,7]. TLR9 discriminates un-methyl-
ated CpG dinucleotides, common in the genomes of most bacteria
and DNA viruses, from the methylated ones in mammalian DNA
[8]. Viral CpG DNA as well as apoptotic host DNA sequences can
rapidly activate TLR9 in pDCs. In SjS, pDCs infiltrate the salivary
gland, inducing high levels of IFNa. This promotes cellular
maturation and survival of B cells, which produce auto-antibodies
to the apoptotic material, worsening disease symptoms and
decreasing saliva secretion [9]. TLR9-driven pro-inflammatory
activation of NFkB may link between the innate and adaptive
immune systems by activating T and B lymphocytes through their
antigen and co-stimulatory receptors. However, NFkB also
activates an alternative or homeostatic pathway which leads to
suppression of pro-inflammatory cytokine production [7,10].
In response to inflammatory stimuli, pDCs express the enzyme
indoleamine 2,3-dioxygenase (IDO), which mediates conversion of
the essential amino acid tryptophan to kynurenine. Modulation of
tryptophan catabolism by IDO is a general mechanism of action of
regulatory T cells (Tregs) via activation of FOXp3. Synthetic
tryptophan metabolites have correspondingly been successful in
treating autoimmune neuroinflammation, apparently caused by
the induction of Treg activity [10,11]. Therefore, we predicted
that the first two modes of TLR9 activation accelerate disease
symptoms, whereas blocking these pathways, or activating the
putative alternative NFkB pathway, may improve salivation.
ACh release from the vagus initiates and monitors saliva
secretion by binding to and activating the muscarinic acetylcholine
(ACh) receptor M3R [3], which stimulates intracellular release of
Ca
++ stores, activates K
+ and Cl
2 channels and enhances fluid
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M3R which could inhibit parasympathetic neurotransmission to
secreting epithelia [13]. Correspondingly, salivary gland cells from
SjS patients require a 10-fold greater ACh concentration than
control cells to elicit the same increase in Ca
++ [14]. This may
explain why there is no meaningful correlation between the degree
of glandular destruction seen in biopsies and impaired salivation in
SjS [2].
ACh has also been shown to activate the a7 nicotinic ACh
receptor (nAChRa7) in lymphocytes and monocytes [15] leading
to down-regulation of NFkB signaling and a decrease in secretion
of pro-inflammatory cytokines [16,17].
Several discriminative subtypes of TLR9 activators can activate
human pDCs. Type-A CpG oligodeoxynucleotides (ODNs) often
spontaneously form large multimeric aggregates and are therefore
retained in the early endosomes of pDCs for relatively long
periods, leading to extended activation of the signal-transducing
complex and robust type a interferone (IFNa) production [18]. In
contrast, Type-B CpG ODNs remain monomeric and are rapidly
trafficked from early to late endosomes, making them poor
producers of IFNa but strong stimulators of B cells [18]. Other
ODNs assume mixed properties, among them BL-7040, previously
known as hEN101, an antisense oligonucleotide against AChE
mRNA which can potentiate cholinergic signaling [19].
In the current study we surmised that functional attenuation of
autonomic neurotransmission to salivary glands, together with
infiltration of pDCs to the gland, contribute to the onset and
severity of the disease. More specifically, we predicted that SjS
involves TLR9 failure, which together with ACh depletion and
acetylcholinesterase (AChE) excess [16] could reduce saliva
secretion. We thus studied the molecular mechanisms underlying
the effect of TLR9 activation on salivary functioning by using
ODN activators and blockers of TLR9 [20] in cultured cells and
mouse models with modified immune functions [21].
Results
BL-7040 is a TLR9 agonist
The BL-7040 oligonucleotide targets human AChE mRNA. It
was designed as an antisense molecule, and correspondingly
reduces AChE activity in various primate systems [19,22]. In
myasthenia gravis patients with characteristic muscle fatigue, orally-
delivered BL-7040 (0.1 mM) improves muscle tone within 30–
60 minutes and for 24 hours at least [22]. The rapid action, low
dose and long-lasting effect raised our concern that additional non-
antisense properties of BL-7040 are involved. To test for possible
TLR-mediated attributes, we administered BL-7040 (100 mM) to
HEK-293 cell lines, each stably expressing a given TLR protein
(TLR 2, 3, 4, 5, 7, 8 or 9) as well as a luciferase reporter plasmid
under an NFkB promoter. In addition, we applied the appropriate
positive ligand control to cell lines expressing the various TLRs, as
described in the methods section (PAM2, Poly I:C, LPS, Flagellin,
R848, and ODN 1826 for TLR 2,3,4,5,7,8 and 9 respectively). As
can be seen in Fig. 1A, each ligand selectively activates its TLR
target. Furthermore, only the cell line expressing TLR9 but no
other TLR was activated by BL-7040, (indicating that BL-7040 is
a specific TLR9 activator, and ruling out the possibility of other
TLR involvement.
Within its 20-nucleotide long sequence, the human-targeted BL-
7040 carries 4 mismatches compared to the mouse AChE mRNA
(Fig. 1B). This would weaken its interaction with murine AChE
mRNA, minimizing but not excluding the possibility that BL-7040
could have an antisense effect in mice (as indicated by molecular
modeling, Fig. 1B). Addition of BL-7040 (1 mM) to cultured RAW
Figure 1. BL-7040 is a TLR9 agonist. A. Luciferase reporter
quantification of NFkB activation in HEK-293 cell lines stably expressing
specific TLR proteins and treated with the established agonists and BL-
7040. TLR activation is given as optical density values (OD). For the
HEK293-TLR2,3,4,5,7,8 and 9 the known ligands were PAM2, Poly I:C,
LPS, Flagellin, R848, and a Type-B CpG (ODN 1826), respectively. HEK-
293 cells expressing the reporter gene alone (TLR-) were used as a
negative control. B. Molecular modeling [22] of BL-7040 (green)
interaction with human AChE mRNA (blue; 227.2 Kcal) compared to
mouse (m)AChE (26.46 Kcal). The A/C mismatch is shown in red. C.
RAW 264.7 murine macrophage-derived cells endogenously expressing
TLR 3, 4 and 9 were treated with BL-7040 (1 mM), LPS (1 mg/ml), CpG-B
(1 mM), poly I:C (2.5 mg/ml) and nitrite levels were determined. The
effect of BL-7040 was abolished by co-administration of the endosomal
maturation inhibitor chloroquine (CQ; 10 mg/ml) (p=0.05) and the TLR9
inhibitor (ODN2088, 0.5 mM) (p=0.05). Error bars represent mean6SEM.
D. CpG-B (p=0.04), BL-7040 (p=0.05) and the human TLR9 inhibitor
(p=0.04) but not the CpG-A decreased AChE activity in human
mononuclear cells. Error bars are mean6SEM. P-values (Student’s t-
test) marked by stars above specific columns show differences from
control levels, whereas p-values marked above line bridges between
columns refer to differences between the groups presented by those
columns. E. Mononuclear cells from C57BL mice displayed decreased
AChE activity when treated with BL-7040 (p=0.02), but this decline was
preventable when cells were co-treated with a TLR9 inhibitor
(p=0.005). Bars are mean6SEM.
doi:10.1371/journal.pone.0028727.g001
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(NO) production similar to LPS (1 mg/ml), CpG-B (1 mM), and
poly I:C (2.5 mg/ml). Furthermore, BL-7040-inducible NO
production was abolished by the endosome maturation inhibitor
Chloroquine (CQ; 10 mg/ml) and the TLR9 oligonucleotide
inhibitor ODN2088 (molar ratio 2:1) (Fig. 1C), demonstrating that
this response is due to the TLR9 activating features of BL-7040.
Primary mononuclear cells from human blood (peripheral blood
mononuclear cells, PBMC) treated with BL-7040, Type-B CpG or
the human TLR9 inhibitor showed decreased AChE activity, in
contrast to a non-significant increase which was seen after
treatment with Type-A CpG. (Fig. 1D), reinforcing the interrela-
tionship between TLR9 activation and the cholinergic pathway.
Similarly, treatment of PBMC from C57BL mice with BL-7040
decreased AChE activity. Co-treatment with BL-7040 and a
TLR9 inhibitor (ODN2088) prevented this decrease in AChE
(Fig. 1E), suggesting again that BL-7040 exerts this effect through
the TLR9 pathway. In mononuclear cells CpG-A activates the
IRF7 pathway, triggering an increase in IFNa levels and elevating
AChE activity, whereas CpG-B activates the classical NFkB
pathway and triggers secretion of proinflammatory cytokines [5].
The observed reduced AChE levels called for an alternative
explanation.
Searching for a possible structural basis for these intriguing
properties of BL-7040, we subjected the BL-7040 oligonucleotide
to heat denaturation, which abolished roughly half of NO
production in BL-7040-treated RAW cells (Figure S1A). In
addition, mass spectrometry analysis demonstrated that BL-7040
includes heavier than monomeric forms which were largely
dissipated following the heating, suggesting that BL-7040 multi-
mers are responsible for the TLR9 activation effect (Figure S1B).
Furthermore, induction of NO by BL-7040 was sensitive to both
chemical and sequence modifications. In RAW cells, BL-7040
with a phosphorothioate backbone of the three 39 bases induced
less NO production than BL-7040 with three 39 2-O-methyl bases.
Also, changing the terminal ends of BL-7040 (bases 1–4 and 19–
20) while keeping the 2-O-methyl protection was ineffective with
regards to NO production, but mutating the central bases (5–15)
while keeping the 2-O-methyl protection substantially reduced
NO production (Figure S1C). Together, these findings indicate
that the TLR9-activating capacity of BL-7040 involves heat-
sensitive multimeric forms and the 10 central nucleotides of this
20-mer molecule.
BL-7040 induces saliva secretion
Previous research suggests that the initiation of Sjo ¨gren’s
Syndrome (SjS) involves production of RNA- or DNA-containing
immune complexes by local apoptotic processes. These complexes
Figure 2. BL-7040 induces saliva secretion and reduces
inflammatory markers. A. NOD mice show reduced salivary response
to pilocarpine compared to BALB/c controls (p=0.05). P-values were
generated by Student’s t-test. B. Western blot of salivary gland extracts
from NOD mice show elevated cleaved caspase-3 levels compared to
BALB/c controls, suggesting increased TLR9 activation, possibly by
apoptotic DNA (p=0.05). C. Experimental layout: NOD and the parent
strain BALB/c mice were injected intraperitoneally with the noted ODNs
for 4 consecutive days. Two hours after the last injection mice were
anesthetized with ketamine/xylazine (Ket/xyl) and injected with
pilocarpine. Saliva secretion and cytokine levels in salivary gland
extracts were determined as detailed in the Methods section. D.
Measurements of saliva secretion in the injected mice. NOD mice
treated with the TLR9 agonist CpG-A displayed decreased saliva
secretion compared to BALB/c controls (p=0.02). CpG-B increased
saliva secretion in NOD (p=0.003) as did BL-7040 (p=0.05) and and
TLR9 inhibitor (p=0.0018) compared to BALB/c (p=0.05) mice. Bars are
mean6SEM. E. F. IFNa and TNFa levels in injected mice. CpG-A
increased both IFNa (p=0.0001) and TNFa (p=0.04) and levels in NOD
mice. IFNa levels were also increased in BALB/C (p=1.5*10-7) mice.
TLR9 inhibitor increased TNFa levels (p=0.005) while maintaining
unchanged IFNa in both NOD and BALB/C mice (p=0.02). CpG-B did
not significantly change IFNa in NOD or BALB/c mice but increased
TNFa (p=0.05) in both mice lines. Treatment with BL-7040 decreased
TNFa and IFNa levels in NOD mice (p=0.014). IFNa levels were
decreased in NOD (p=0.0022) but did not change in BALB/c mice
treated with BL-7040. Bars are mean6SEM.
doi:10.1371/journal.pone.0028727.g002
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salivary glands, production of yet more IFNa, and enhanced
infiltration of T-cells and macrophages into the diseased glands
[9,24]. NOD mice, used as a model to study SjS features [25],
presented reduced salivary functioning compared to BALB/c
controls (p=0.05; Fig. 2A), and their salivary glands showed
higher levels of cleaved caspase-3 (p=0.05), suggesting accelerated
apoptosis (Fig. 2B).
Different CpG ODNs initiate different physiological mecha-
nisms capable of controlling both inflammation and autoimmunity
[26] as well as an immunosuppressive response [27]. To test
whether BL-7040 activation of TLR9 plays an active role in
controlling immune and salivary functioning and is modified in
SjS, we tested the effect of TLR9-affecting ODNs on saliva
secretion of NOD mice compared to BALB/c controls (Fig. 2C)
[20]. Given that the endosomal maturation inhibitor hydroxy-
chloroquine inhibits TLR9 activation and is a common treatment
for SjS [27], we injected NOD and BALB/c mice with ODN2088,
which dramatically increased salivation in NOD mice (p=0.0018)
(Fig. 2D).
The IFNa-activating CpG-A triggered a decline in salivary
functioning in NOD mice compared to saline (p=0.02), in
agreement with reports that IFNa excess is associated with
attenuated saliva secretion [10]. As expected, CpG-A-treated
BALB/c and NOD mice also displayed increased levels of IFNa
(p=0.0001and p=1.5*10
27respectively) and TNFa (p=0.05 and
p=0.04, respectively). In comparison, NOD mice treated with
CpG-B (5 mg/kg) [28] displayed significantly increased saliva
secretion (p=0.003), with unchanged IFNa and elevated TNFa
levels (p=0.05). In contrast, BL-7040 (5 mg/Kg), while markedly
enhanceing saliva secretion in NOD (p=0.001), caused no
elevation in TNFa or IFNa (Fig. 2D–F). These results suggest
an alternative TLR9 pathway activation which is particularly
robust under autoimmune conditions.
BL-7040 activates the alternative TLR9 pathway
Canonical NFkB activation induces pro-inflammatory media-
tors (e.g. TNFa, NO) downstream of TLR9, whereas alternative
signaling involves (among others) phosphorylation of NIK [29]
and may account for the apparent ability of TLR9 activation to
restore homeostasis by inducing the production of proteins such as
IDO. Immunocytochemistry for phosphorylated NIK (pNIK) and
IDO was performed on mononuclear cells from C57BL mice
treated with BL-7040 alone or together with a TLR9 inhibitor.
High pNIK and IDO levels were observed following treatment
with BL-7040, peaking at 0.1 mM. Co-treatment with the TLR9
inhibitor completely abolished pNIK and IDO induction,
reinforcing the TLR9 dependence of this effect (Fig. 3A, 3B).
These findings raised the question whether IDO and pNIK are
also elevated in mouse salivary glands treated with CpG-B and
BL-7040. We found that both CpG-B (p=0.01, 0.003) and BL-
7040 (p=0.01, 0.04) elevated IDO (Fig. 4A, 4B) and pNIK levels
(Figure S2A, S2B) in BALB/c (p=0.05, 0.01) and NOD
(p=0.001, 0.05) mice. This further suggests that alternative NFkB
activation is reinforced under impaired salivary conditions.
TLR9
2/2 mice show impaired salivary functioning
To determine if TLR9 is essential for the BL-7040 effect we
treated C57BL and TLR9
2/2 mice with BL-7040. C57BL mice
showed a strong yet short-lasting salivary response. In contrast,
TLR9
2/2 mice showed consistently lower salivary activation and
were totally refractory to BL-7040 treatment (Fig. 5A, 5B).
Together, this demonstrates that BL-7040 responses are limited to
TLR9-expressing mouse strains, albeit with strain-specific kinetics.
Human SjS salivary glands show elevated AChE and
decreased alternative markers
Salivary gland biopsy sections from primary SjS patients and
Sicca syndrome controls were tested for markers of TLR9 activity
and cholinergic signaling. The rational for using tissue samples
from SjS patients without anti-Ro/SSA and anti-La/SSB
antibodies was to avoid the possibility that our observations were
related to the immune response rather than to the SjS phenotype
itself [30]. Although these patients were in preliminary disease
stages and tested negative for anti-Ro/SSA and anti-La/SSB they
displayed increased markers of the canonic TLR9 pathway,
compatible with previous reports [31]: IL-1b was elevated in SjS
gland ducts (p=0.05), Fig. 6A) and NFkB (P65) was increased in
both acini and ducts (p=0.0002) (Fig. 6B). However, the
alternative markers pNIK and IDO were decreased in SjS
biopsies (p=0.0001and p=7.5*10
212, respectively) (Fig. 6C,
6D). Finally, in human PBMC, BL-7040 induced FOXp3 mRNA
levels, known to be activated by IDO [32], as did CD40L, a
known activator of Tregs. This increase was not detected with any
of the other CpGs (Fig. 6E).
Last, we tested the possibility that together with infiltrating
lymphoid cells and decreased saliva secretion caused by inflam-
mation, AChE-induced suppression of cholinergic activity may
‘‘shut down’’ fluid secretion. Labial gland biopsies from SjS
patients showed elevated AChE expression in both acini
(p=0.002) and ducts (p=0.025) (Figure S3B). AChE-S mRNA
levels remained unchanged (Figure S3D) while AChE-R mRNA
levels were increased (Figure S3C). This would increase the
secreted soluble monomers of the AChE-R variant, which can
readily access the neuron-gland interaction sites. Thus, as in other
diseases (e.g. myasthenia gravis [33]), AChE over-expression is
accompanied by changes in alternative splicing from the common
AChE-S to the normally rare AChE-R variant.
Discussion
In our research we demonstrate that BL-7040 is a TLR9-
specific ligand that can simultaneously suppress pro-inflammatory
functions and shift NFkB from the pro-inflammatory canonical to
the alternative pathway. We show that this activation of the NFkB
alternative pathway leads to suppression of the immune system
activator IFNa and increases IDO levels. We also show severe
impairments of salivary functions in TLR9
2/2 mice and
demonstrate CpG-induced, TLR9-dependent restoration of this
alternative pathway, which can enhance saliva secretion in
malfunctioning glands of NOD mice.
IFNa is perceived as the functional bridge between pDCs and
Tregs, and is linked with resistance to specific forms of immuno-
pathogenesis and infection [34]. Total blockade of the IFNa
pathway improves disease symptoms, as in the case of SjS patients
treated with Hydroxychloroquine. This compound attenuates
endosomal maturation [27]; however, since the endosome is
important for many other cellular functions, its chronic systemic
blockade might have both beneficial and harmful effects [35,36].
In contrast, BL-7040, with its unique chemical protection pattern
and multimeric structure, should be considered as an advanta-
geous therapeutic entity (Figure S4).
That both inhibition (by a TLR9 inhibitor) and non canonic
NFkB activation (by BL-7040) decrease AChE activity suggests
that either complete TLR9 blockade or TLR9-mediated alterna-
tive activation of NFkB may suppress the downstream regulator(s)
controlling AChE levels (such as microRNA-132 [37]); that both
of these together have no effect suggests that the two pathways
TLR9 Activation Enhances Salivary Functioning
PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e28727Figure 3. Low dose BL-7040 activates the alternative TLR9 pathway in mouse mononuclear cells. A. Immunocytochemistry for pNIK in
bone marrow macrophages from C57BL mice treated for 1 hr with BL-7040 (0–10 mM), with or without TLR9 inhibitor (0.1 mM). Immunocytochemistry
for IDO in bone marrow-derived dendritic cells treated with BL-7040 (0–10 mM) with or without a TLR9 inhibitor. The presented microphotographs are
representative examples from 5 different samples in 3 biological repeats. Cells grown on glass slides were dried, cover-slipped, and analysed was with
a4 0 6/1.3 oil immersion objective using a FV-1000 confocal attachment (Olympus, Japan) to an IX81 inverted microscope. Excitation wavelengths for
Cy2 and Cy3 were 488 and 543 nm, respectively. Emissions were collected using the 505–525 nm and 560–620 nm filters, respectively. 50 cells were
measured in each image. 3–7 images were analyzed from each treatment group. B. Quantification of immunohistochemistry for both pNIK and IDO
(0.1 mM). For quantification of pNIK and IDO immuno-staining, at least three different preparations were sampled from each treatment. Using an
ANALYSIS image analysis software, the labeled cells were encircled and the percent of immunostained area was calculated. P values represent non-
treated vs BL-7040 treated cultures. * P,0.05, ** P,0.001, *** P,0.0005. Bars are mean6SEM.
doi:10.1371/journal.pone.0028727.g003
Figure 4. BL-7040 activates the alternative NFkB pathway in
murine salivary glands. Western blots of gland extracts from BALB/c
and NOD mice receiving the stated treatments are shown. Bands are
taken from the same gels but from non-adjacent lanes. The western
blot analysis was done on protein samples extracted from all mice
tested for saliva secretion (9–12 mice per treatment), and representative
gels are displayed. Analysis of the gels was done using ImageJ. A. BL-
7040 and CpG-B elevated IDO (p=0.01, 0.04) in BALB/c mice. B. BL-7040
and CpG-B increased IDO (p=0.01, p=0.003) in NOD mice.
doi:10.1371/journal.pone.0028727.g004
Figure 5. The BL-7040 salivation effect fails in TLR9
2/2 mice.
Cumulative (5A) or fold change values from time -0- of salivary activity
(5B) were plotted, and the statistical significance of the difference
between the measured values of wild type and TLR9-/- mice was
performed using Mann-Whitney U-test, ANOVA and post-hoc analysis
(Tukey). Significance was determined at the level of p,0.05. Statistical
analysis was performed by SPSS 16. Normalization was confirmed by
MatLab. A. BL-7040 increased saliva secretion in C57BL but not in
TLR9
2/2 mice (P=0.003), which also showed lower baseline salivary
secretion. Bars are mean6SEM. B. BL-7040 increased saliva secretion in
C57BL mice but showed a decay over time, while no change was seen
in TLR9
2/2 mice. Bars are mean6SEM.
doi:10.1371/journal.pone.0028727.g005
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the regulators.
The autonomic nervous system releases ACh continuously from
the vagus, activating the M3R receptors in salivary gland cells and
leading to saliva production. A finely-tuned balance between this
brain-to-body signaling process and secretion of pro-inflammatory
cytokines, which attenuate saliva production, is essential for proper
regulation of this autonomous function. The fact that salivary
gland cells isolated from SjS patients show over-expression of
M3R could reflect a feedback response to disease-associated
suppression of ACh release [12,20]. This suppression could be due
to enhanced ACh degradation by AChE which terminates
cholinergic signaling [13]. In accordance, we show that salivary
gland biopsies from SjS patients display higher levels of AChE
compared to Sicca syndrome controls. Additionally, age-related
increases in circulation AChE and pro-inflammatory cytokines
[38] indicate parallel acceleration of salivary mal-functioning. The
consistently elevated AChE in females compared to males [39]
may be relevant for the gender-related incidence of SjS [1].
General impairments in cholinergic signaling and consequent
enhancement of immune functions may hence facilitate SjS
glandular hypofunction, disparate from the effect of anti-M3R
auto-antibodies, which cause at least part of the SjS symptoms.
Our current study raises the possibility of an inter-relationship
between TLR9, cholinergic and immune functions as a powerful
mechanism for monitoring saliva secretion.
IKKa, which is downstream to TLR9, is required for the
development of self-tolerance, whereas IKKb mediates NFkB
activation in response to pro-inflammatory stimuli and is crucial
for canonic pathway activation [40,41,42]. We show that SjS
patient biopsies have an altered balance between canonic and
alternative NFkB signaling. IL-1 and NFkB (P65) – canonic
pathway markers – are elevated, whereas pNIK and IDO –
alternative pathway markers – are reduced. TLRs, NFkB and
IDO are intimately linked in the prevention of immuno-
pathogenesis that involves function of Tregs [10,43] and elevated
IDO levels have been shown to activate Tregs, known to maintain
tolerance to self antigens [10]. We show that the Treg-
characteristic FOXp3 translational activator was increased as a
result of BL-7040 treatment of human Peripheral blood mononu-
clear cells. This could potentiate the alternative pathway, leading
to resolution of early inflammatory processes and to the onset of
tolerance to self [40,44].
In conclusion, TLR9 activation of the NFkB canonical pathway
can lead to constitutive over-production of pro-inflammatory
cytokines and weakened cholinergic signaling. Parallel phenomena
are associated with a number of chronic inflammatory disorders,
including rheumatoid arthritis and Crohn’s disease [45]. Thus,
interference with neuroimmune impairments, including in early
stages of SjS, should be targeted to both their neuronal and
immune aspects.
Although the focus of our manuscript is of a basic nature we
suggest that it may have therapeutic applications. There are still
many questions left unanswered regarding the clinical aspects of
BL-7040, including a more detailed clinical and histolopathologi-
cal assessment of the patients, analysis of AChE levels and local
IFNa production, and the association of non-canonical NFkB
markers with different stages of Sjogren’s syndrome. Further
studies will hence be required to determine if BL-7040 could be
beneficial for these syndromes as well as for neurodegenerative
diseases in which neuroinflammation is involved, such as
Alzheimer’s or Parkinson’s diseases [46,47].
Materials and Methods
Human labial gland samples
Labial glands were collected from the lower lip of 15 SjS
patients (with pathological diagnosis, without ribonuclear antibod-
ies) and 12 Sicca syndrome patients under local anaesthesia at the
Queen Elizabeth Hospital (Woodville South, Australia). SjS
patients were defined according to the revised 2002 American
European Classification criteria (Table S1). The clinical definition
of SjS was largely based on the salivary malfunctioning criterion as
assessed by expert physicians. The study was approved by the local
Institutional Review Board (Application number 2008124, see
description of patients in Table S1).
Figure 6. Sjogren’s disease biopsies show elevated inflamma-
tory markers and suppressed alternative NFkB markers. The
presented microphotographs are representative examples from 15
different SjS patients and 12 Sicca syndrome control samples in 3
biological repeats. Biopsies stained for the specific proteins were
acquired with a 406/1.3 oil immersion objective using a FV-1000
confocal attachment (Olympus, Japan) to an IX81 inverted microscope.
Excitation and emission wavelengths for Cy2 and Cy3 are as described
in Figure 3A. At least 3 acini and 2 ducts were measured in each image.
12–15 images were analyzed of each treatment group. A. IL-1b was
increased in SjS ducts (p=0.05) but not acini compared to Sicca
syndrome controls. B. The p65 fragment of NFkB was increased in SjS
compared to Sicca syndrome controls (p=0.0002). C. pNIK levels were
decreased in SjS patients compared to Sicca syndrome controls
(p=0.0001). D. IDO levels were decreased in SjS patients compared
to Sicca syndrome controls (p=7.5*10
212). E. PBMN cells displayed
elevated FOXp3 levels after activation by CD40L or BL-7040. Treatment
with CpG type A, B and TLR9 inhibitor decreased FOXp3 levels.
doi:10.1371/journal.pone.0028727.g006
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Female Non-Obese Diabetic (NOD) mice and control BALB/c
and C57BL mice (approximately 5 months old) were obtained
from Harlan (Rehovot, Israel). While NOD mice also show
characteristic features of diabetes, these progress at a later age than
that used for our current study [25], and there were no insulin
injections involved which could potentially influence the TLR
modulations. TLR9
2/2 mice were gratefully received from Dr.
Eithan Galun, (HU-HMS Jerusalem). 9–12 mice per experimental
group were employed. Salivation experiments were repeated 3
times, with 3–4 mice per treatment. All experiments were carried
out according to the Animal Care and Use Committee of The
Hebrew University, Jerusalem (approval # NS-04-21).
Mouse submandibular gland samples
Mice were sacrificed by cervical dislocation and their subman-
dibular salivary glands were removed and immediately homoge-
nized in 200 ml per gland of a high-salt/detergent buffer (0.01 M
Tris, 1 M NaCl, 1% Triton X-100, 1 mM EGTA, pH 7.4) [37].
Cells
HEK-293 and the murine macrophage-derived cell line RAW
264.7 were used. A human salivary gland (HSG) cell line was
gratefully received from Dr. A. Palmon (HU-HMS, Jerusalem).
Human and mouse primary mononuclear cells were prepared as
described previously [37].
TLR screening
TLR activators were tested on recombinant HEK-293 cell lines
stably expressing a given functional TLR protein as well as a
luciferase reporter gene driven by the NFkB promoter. HEK293
cells express no TLRs, which makes it an excellent cell line for
over-expression of exogenous TLRs. The exogenous expression of
the noted TLRs was validated in each cell line separately by
specific qPCR assays (data not shown). TLR activation results are
given as optical density values (OD). For positive controls, each
HEK293-TLR cell line was induced with a ligand specific to the
expressed transgenic TLR. Positive control ligands were: TLR2;
PAM2 (100 ng/ml), TLR3; Poly I:C (100 ng/ml), TLR4; LPS
K12 (100 ng/ml), TLR5; Flagellin (1 mg/ml), TLR7; R848
(10 mg/ml), TLR8; R848 (10 mg/ml), TLR9; ODN 2006 (CpG-
B) (10 mg/ml). 20 ml of each ligand was used to stimulate cell lines
in 200 ml reaction volume. BL-7040 concentration for induction
was 100 mM. The negative control was a HEK-293 cell line
expressing the reporter gene alone. For each cell line the reporter
signal under non-induced conditions was taken as the baseline
value.
Immunocytochemistry, in situ hybridization and
cholinesterase catalytic activities
Polyclonal antibodies against IL-1b (R&D, Abingdon, UK, 1:20
dilution); AChE N19 (Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA, 1:20), pNIK (Santa Cruz, 1:50), FOXP3 (eBioscience,
San Diego, CA, USA, 1:50) and IDO (Millipore, Billerica, MA,
USA, 1:50), were used as described [48]. In-situ hybridization and
cholinesterase activity measurements were carried out as described
previously [46].
Oligonucleotides
BL-7040 was obtained from Avecia (Cambridge, UK) and
ODN 1826, 1585, 2088, 2006, 2216 and TTAAG from Invivogen
(San Diego, California, USA). All were endotoxin-free. Table S2
shows the sequences and chemical protection modes of the ODNs.
Mouse saliva secretion
Mice (n=11 per group) were intraperitoneally administered with
variousODNs (Table S2)orsaline for four consecutivedays. On the
fourth day, two hours after ODN injection, mice were anesthetized
with Ketamine-Xylazine (100 mg/Kg and 10 mg/Kg, i.p) and
injected with 15 mg/kg pilocarpine to induce salivation. Mice were
placed on an inclined surfacewiththeir heads facing downward and
a pre-weighed piece of Whatmann paper wasplaced intheir mouth.
Papers were changed and weighed every 5 min (last change at
30 min post-pilocarpine injection).
Western Blots
Salivary gland homogenates were separated by standard SDS-
PAGE as previously described [48]. Proteins were visualized using
antibodies to pNIK (1:500), a-Tubulin (1:1000) (sc-12957 and sc-
32293, Santa Cruz) and IDO (1:500) (AB9900, Millipore, Billerica,
MA) followed by peroxidase-conjugated antibodies (1:10,000, Jackson
Laboratories, West Grove, PA) and enhanced chemiluminescence
(ECL) (EZ-ECL, Biological Industries, Beit-Haemek, Israel).
Inflammatory biomarkers
To determine NO production in macrophage cultures the stable
breakdown product nitrite was measured using the Griess method
[25]. 100 ml of each sample +100 ml of Griess reagent (1%
sulfanylamide/0.1% naphthylethylenediamine dihydrochloride/
2.5% H3PO4) were incubated for 10–20 min at room temp. and
absorbance (546 nm) was determined using a microplate reader
(Genios Pro, Tecan, Maennedorf, Switzerland). IFN-a and TNF-a
were measured by ELISA according to manufacturer’s procedures
(PBL interferon source, NJ and eBioscience, Hatfield, UK).
Confocal Microscopy
Cy2 and Cy3 fluorescence in tissue sections were determined
using an FV-1000 confocal attachment (Olympus, Japan) to an
IX81 inverted microscope. Excitation wavelengths for Cy2 and
Cy3 were 488 and 543 nm, respectively. Emissions were collected
using the 505–525 nm and 560–620 nm filters, respectively. At
least 10 acini and 6 ducts per slide were analyzed.
Statistical analysis
Statistical analysis was performed by SPSS using unpaired
Student’s t-test, Mann-Whitney U-test, ANOVA and post-hoc
analysis (Tukey). Significance was determined at the level of
p,0.05. Normalization was confirmed by MatLab.
Supporting Information
Figure S1 BL-7040 characterization. A. Heating of BL-
7040 (95uC for 10 minutes) did not abolish induced nitrite
production by RAW 264.7 cells. B. Mass spectrometry of BL-
7040 reveals spontaneous dimerization in PBS. C. Nitrite
production in RAW 264.7 cells following exposure to BL-7040,
phosphorothioated BL-7040 (PS), BL-7040 with sequence alter-
ations in ends or center region and negative control oligonucle-
otide. Bars are mean6SEM.
(TIF)
Figure S2 Western blots of gland extracts from treated
mice. Elevation of pNIK suggests homeostatic TLR9
effects on salivary glands. A. BL-7040 and CpG-B
ODN1826 elevated pNIK (p=0.01, 0.05) in BALB/c mice. B.
BL-7040 and CpG-B ODN1826 increased pNIK (p=0.001,
p=0.05) in NOD mice.
(TIF)
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shift in AChE splicing. A. AChE pre-mRNA can undergo
alternative splicing giving rise to the predominant AChE-S and the
disease-inducible AChE-R splice variants. B. AChE protein levels
increase in both acini (p=0.04) and ducts (p=0.02) in biopsies of
SjS patients compared to Sicca syndrome controls C. AChE-R
mRNA (p=0.002, p=0.025) but not AChE-S mRNA was
increased in both SjS acini and ducts.
(TIF)
Figure S4 Summary figure. The scheme shows three
alternative routes for downstream activation of TLR9-mediated
signals. Type-A CpG ODNs activate the IRF7 pathway increasing
IFNa levels (shown in blue). Type-B CpG ODNs induce the
canonic NFkB pathway (shown in red), and BL-7040 can activate
the homeostatic NFkB pathway (shown in black) similarly to
CD40L, elevating IDO levels and possibly Treg activation.
(TIF)
Table S1 List of biopsies from SjS patients.
(DOC)
Table S2 CpG sequences.
(DOC)
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